secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001140361-23-024136
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q1 2023 net loss $2.95M; Health Canada approves FemaSeed & FemCerv
--------------------------------------------------------------------------

- Net loss of $2,946,257 ($0.25 basic & diluted EPS) vs $2,883,030 ($0.24) YoY.
- Revenue $293,984, down 8.5% YoY; U.S. sales up 11.6%, international sales nil.
- Raised $3.9M in registered direct offering closed April 20, 2023; cash runway into Q2 2024.
- Health Canada approved FemaSeed (infertility) and FemCerv (cervical sampler) in April/May 2023.
- Cash and equivalents $10.2M as of March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123024136/0001140361-23-024136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123024136/brhc20052828_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-024136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer